Von in Medical Technology

IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile

... of the leading surgeons in Chile, Dr. Sebastian von Unger, has performed the first case in the world ... runs to the little finger. According to Dr. von Unger, "With traditional methods of treating ... procedure to remove them. According to Dr. von Unger, "The instrumentation is intuitive and easy ...

Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings

... cancer drugs I have ever studied," said Daniel D. von Hoff, M.D., lead Phase 1 investigator for ... be presented by featured speaker, Dr. Daniel D. von Hoff, at an investor event on June 2, 2008. The ... Mulay, M., Eldon, M., Dhar, S., Acosta, L., von Hoff, D.D., "Phase 1 Dose-finding and ...

White Nose Syndrome: Is Pennsylvania Next?

... yet to shed further light on anything. As Susi von Oettingen, a USFWS endangered species biologist, ... New York, Vermont and Massachusetts," explained von Oettingen. "We're optimistic the Game Commission ... can prepare to deal with WNS." Of course, von Oettingen, also is hoping for the best. "My hope ...

Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)

... The Webcast will include a presentation by featured speaker Dr. Daniel D. von Hoff, M.D., F.A.C.P, the lead investigator for the NKTR-102 Phase 1 trial. Dr. von Hoff is Physician-in-Chief and Senior Investigator at the Translational ...

Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research

... of Pancreatic Cancer" / Leaders: Craig B. Thompson, M.D., Director, Abramson Cancer Center at the University of Pennsylvania , and Daniel D. von Hoff, M.D., Senior Investigator and Physician in Chief at the Translational Research Genomics Institute (TGen). The projects ...

Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine

... development of vaccines against infectious diseases with significant unmet medical need," commented Intercell's Chief Scientific Officer, Alexander von Gabain. Although vaccines against Streptococcus pneumoniae are available, they cover only a restricted number of the more than 90 known ...

CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency

... and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the ...

Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors

... are past the age of 40 and are twice as likely to be men. Other risk factors include smoking, obesity, high blood pressure, long-term dialysis and von Hippel-Lindau syndrome. About the Society of Interventional Radiology Interventional radiologists are physicians who specialize in ...

Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2

... As such, CX-4945 is a truly novel therapeutic, particularly against cancers and in other indications mediated by IL-6 and IL-8," added Dr. Daniel von Hoff, Cylene's Co-Founder and Vice President, Medical Affairs. About CX-4945, an oral CK2 protein kinase inhibitor CX-4945 is a ...

PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru

... office marks a significant opportunity for clients to further expand their clinical development programs throughout Latin America," said Josef H. von Rickenbach, Chairman and Chief Executive Officer of PAREXEL. "Our experts in Latin America manage complex clinical trials on a regional and worldwide ...

Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer

... The drug also increases the therapeutic benefits of radiotherapy. The Phase I trial is currently being conducted under the supervision of Daniel von Hoff, M.D. at TGen Clinical Research Services at The Virginia G. Piper Cancer Center at Scottsdale Healthcare, Mayo Clinic Scottsdale and the ...

Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program

... IC31(R), a strong TLR agonist. Furthermore our vaccine in future trials may be combined with standard therapy or novel antivirals." states Alexander von Gabain, Chief Scientific Officer of Intercell. Although options for the treatment of chronic Hepatitis C with Interferon/Ribavirin have improved, ...

n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure

... studies of n-3 PUFAs in other cardiovascular indications may unveil additional benefits in patients with cardiovascular diseases. Professor Clemens von Schacky, Head of Preventive Cardiology, University of Munich, Germany, also reviewed the GISSI-HF trial outcomes and presented the implications of ...

Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer

... treatment options for non- small cell lung cancer because current treatment strategies have only a minimal impact on survival," said Joachim von Pawel, M.D., a principal investigator in the study from the Asklepios Fachkliniken Munchen-Gauting, Germany. "The majority of patients who are newly ...

CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema

... and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the ...

CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity

... products and related services. The company's therapies are used in the treatment of rare diseases such as immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the ...

CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema

... and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the ...

Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease

... and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the ...

Ardea Biosciences' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients

... to have a very favorable profile. We are very excited to be selected to participate in the Phase 1 program for this interesting molecule," said Dan von Hoff, MD, Physician in Chief, Translational Genomics Research Institute and Chief Scientific Officer, Scottsdale Healthcare. About RDEA119 and ...

Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals

... company is located in Cary, North Carolina. For more information, please visit http://www.tranadiscovery.com . Media Contacts: Karl von Gunten (919) 931-1434 Rhonda Jung (205) 581-2317 karlvongunten@tranadiscovery.com jung@southernresearch.org ...

Prolexys Pharmaceuticals Initiates Phase 1 Study

... about our participation in the study of this interesting new agent with what appears to be a unique mechanism of action," said Dr. Daniel von Hoff, Physician-in-Chief and Director of Clinical Research at TGen, and the principal investigator for the study at Scottsdale Healthcare. "Rarely ...

Intercell AG: Novel tuberculosis Vaccine Shows Promising Immunogenicity and Safety Profile

... base of our preclinical data”, explains Peter Andersen, Director of Vaccine Research and Development, SSI. Intercell’s CSO, Alexander von Gabain, commented: “Our adjuvant IC31™ proved an outstanding profile to stimulate a strong T-cell immune response in humans as ...

FDLI 50th Annual Meeting Heralds New ERA in Healthcare Innovations, FDA Regulations

... resources to deal with the challenges led by scientific breakthroughs increasing health benefits but also risks in foods, drugs and devices, von Eschenbach told the industry representatives, compliance officers, health policymakers, physicians, regulators and attorneys attending the ...

FDA Announces Audio Broadcasts on Emerging Drug Safety Information

... . "FDA's highest priority is to protect and enhance the health of the American public," said Andrew C. von Eschenbach, M.D., Commissioner of Food and Drugs. "The service contributes to this goal by providing a new venue for busy health care ...

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel

... presented findings on a variety of disease states including lung, gastrointestinal, genitourinary, gynecologic, breast and melanoma. -- Daniel von Hoff, M.D., Chief Scientific Officer: The Complete Phase lb Clinical Trial: A Method to Accelerate New Agent Development -- Michael ...

Study Shows Advantages of Complete Phase Ib Trial Over Separate Phase I Trials

... in our poster will significantly shorten the time it takes to bring new therapies into the daily care for patients with cancer," said Dr. von Hoff. Phase I trials are the initial step in testing new treatments in humans. Their main focus is to evaluate a drug's safety, including safe ...

Archemix Announces Completion of Phase 1 Trial of ARC1779

... therapeutic, ARC1779. ARC1779 is designed to selectively block the activation, adhesion and aggregation of platelets by inhibiting the binding of von Willebrand Factor (vWF) to the GPIb receptor on platelets. Activated vWF is scientifically recognized as the first stage of arterial thrombus ...

Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action

... of molecules with novel mechanisms of action, such as PRLX 93936 in patients with pancreatic cancer and other solid tumors," said Dr. Daniel von Hoff, Principal clinical investigator of PRLX 93936, and TGen's Physician-in-Chief and Director of TGen's Clinical Research Service in Scottsdale, ...

Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)

... programme, ALX-0081, an anti-thrombotic treatment. ALX-0081 is a novel ´first-in-class´ therapeutic Nanobody® targeting von Willebrand Factor (vWF), which can reduce the risk of thrombosis in patients with acute coronary syndrome. The Phase I study in healthy volunteers ...